Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook, LinkedIn, and YouTube.SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm's fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET.
2024年8月26日加州南舊金山（GLOBE NEWSWIRE）-- 標準生物工具公司（Nasdaq:LAB）今天宣佈，其總裁兼首席執行官Michael Egholm博士將在即將於9月4日（星期三）至9月6日（星期五）在紐約市舉行的摩根士丹利第22屆全球醫療保健大會上發表演講。Egholm博士的爐邊談話將於2024年9月6日星期五上午8:30舉行。
The presentation will be webcast live and available on the Investor Relations page of the Company's website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
演示將通過網絡直播，並可在公司網站的投資者關係頁面的活動與演示上觀看。網絡直播的錄像將被存檔，並可在標準生物工具投資者關係頁面investors.standardbio.com上觀看。
About Standard BioTools Inc.
關於標準生物工具股份有限公司。
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook, LinkedIn, and YouTube.
Standard BioTools Inc.（納斯達克：LAB）是SomaLogic Inc.的母公司，此前被稱爲Fluidigm Corporation，擁有一系列基本的、標準化的下一代技術，幫助生物醫學研究人員更快、更好地開發藥物。作爲領先的解決方案提供商，該公司使用其專有的質量細胞術和微流控技術提供可靠和可重複的健康和疾病見解，幫助將科學發現轉化爲更好的患者成果。Standard BioTools與全球領先的學術界、政府、製藥、生物技術、植物和動物研究和臨床實驗室合作，專注於轉化和臨床研究中最緊迫的需求，包括腫瘤學、免疫學和免疫療法。了解更多信息，請訪問standardbio.com或在X、Facebook、LinkedIn和YouTube上與我們聯繫。
For Research Use Only. Not for use in diagnostic procedures.
僅用於研究。不能用於診斷程序。
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. 2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
可能適用有限使用標籤許可證和其他條款：standardbio.com/legal/salesterms。專利和許可信息：standardbio.com/legal/notices。
商標：standardbio.com/legal/trademarks。任何其他商標均爲其各自所有者的唯一財產。2024年Standard BioTools Inc.（前名Fluidigm Corporation）。保留所有權利。
Investor Contact:
投資者聯繫：
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
大衛·霍姆斯
吉爾馬丁集團有限責任公司
(332) 330-1031
ir@standardbio.com
